Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of AdvanCell.

    Client Virtual Booth

    ADVANCELL

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    AdvanCell
    Australia Flag
    Country
    Country
    Australia
    Address
    Address
    Level 7, Macquarie House, 167 Macquarie Street, Sydney, NSW, 2000
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://advancell.com.au/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands

    Details:

    The collaboration aims on the development of a global 212Pb radioisotope and radioligand supply chain to specifically support the development and commercialization of 212Pb-labeled radioligands including, 212Pb-ADVC001, a best-in-class treatment for metastatic prostate cancer.


    Lead Product(s): 212Pb-ADVC001

    Therapeutic Area: Oncology Product Name: 212Pb-ADVC001

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Point Biopharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration June 26, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    AdvanCell Closes A $18M Series B Funding Led by Morningside

    Details:

    Series B financing will accelerate growth and advance lead clinical program 212Pb-ADVC001 a best-in-class treatment for metastatic prostate cancer, expand manufacturing platform footprint and progress internal and partnership programs.


    Lead Product(s): 212Pb-ADVC001

    Therapeutic Area: Oncology Product Name: 212Pb-ADVC001

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Morningside

    Deal Size: $18.0 million Upfront Cash: Undisclosed

    Deal Type: Series B Financing August 23, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    fermion-oy-2024-05-13

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search